US › Healthcare

Aytu BioScience Inc (AYTU)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$2.21-1.78%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$12.4M
Revenue YoY
-32.7%
Net profit
$-5.6M
Profit YoY
-240.7%
EPS
$-0.41
EPS estimate
$-0.42
Net margin
-45.3%

EPS came in at -0.41 against a street estimate of -0.42 — a beat of 2.4%.

Key statistics

Market cap
$24.1M
Forward P/E
27.9
P/B
0.68
Book value
$3.27
EPS (TTM)
$-4.61
52-week high
$3.07
52-week low
$1.65
50-day MA
$2.18
200-day MA
$2.37
Beta
0.26

Analyst view

Analysts rate Aytu BioScience Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $9.50.

Shareholding

Insiders
8.98%
Institutions
36.77%

Largest institutional holders

FundStake
Nantahala Capital Management, LLC10.13%
Stonepine Capital Management Llc7.38%
Awm Investment Company Inc5.77%
Diadema Partners LP3.29%
Vanguard Group Inc2.60%
Vanguard Capital Management, LLC2.43%
CROWN ADVISORS MANAGEMENT, INC.1.35%
Two Sigma Investments LLC1.14%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aytu BioScience Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.